文献速递鼻科

EUFOREA 2017辩论:变应性鼻炎治疗中MP-AzeFlu的定位与未来趋势

Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis.
PubMed 文献 · Rhinology · 2019-01-01

本文总结该辩论,回顾近期数据,探讨专家解读及其如何被纳入AR管理指南和临床决策支持系统(CDSS)。

要点

  • ARIA指南将MP-AzeFlu列为AR一线治疗,治疗前2周优先于鼻内糖皮质激素(INS)。
  • AR CDSS推荐MP-AzeFlu作为VAS评分低于5/10 cm患者的一线治疗之一。
  • 专家认为MP-AzeFlu起效快、控制症状迅速,可能对共病哮喘控制影响更大。

核心结论

  • MP-AzeFlu在AR治疗中具有重要作用,尤其适用于需要快速起效和针对突破性症状的患者。

主要发现

  • ARIA指南将MP-AzeFlu列为AR一线治疗,治疗前2周优先于INS。
  • AR CDSS推荐MP-AzeFlu作为VAS评分低于5/10 cm患者的一线治疗之一,VAS评分等于或高于5/10 cm时与INS一同优先推荐。
  • 专家小组认为MP-AzeFlu具有5分钟起效、15分钟提供临床相关症状缓解、不到3天实现AR控制的特点。
  • MP-AzeFlu靶向鼻高反应性(NHR),可能有助于控制未控制的AR和突破性症状。
  • MP-AzeFlu比INS单药或INS联合口服抗组胺药提供更有效的AR症状缓解。

关键数值与推荐

  • ARIA指南:MP-AzeFlu为AR一线治疗,治疗前2周优先于INS。
  • AR CDSS:VAS评分低于5/10 cm,MP-AzeFlu为一线治疗之一;VAS评分等于或高于5/10 cm,MP-AzeFlu与INS一同优先推荐。
  • MP-AzeFlu:5分钟起效,15分钟提供临床相关症状缓解,不到3天实现AR控制。

临床怎么用

  • AR管理应尽可能简单,专家对采用一刀切方案还是阶梯方案存在不同偏好。
  • 需改变AR管理思维,承认多数患者按需用药并使用多种治疗。
  • 需要起效非常快且针对突破性症状的AR药物,MP-AzeFlu可在此发挥作用。
  • 共病哮喘患者中MP-AzeFlu可能比INS对哮喘控制影响更大,但需临床数据支持现有药物经济学证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2nd Rhinology Future Debate, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases) was held in Brussels in December 2017. One of these debates addressed the position of MP-AzeFlu in allergic rhinitis (AR) treatment. The current article summarizes this debate; reviewing recent data, and exploring how this has been interpreted by experts and incorporated into AR management guidelines and a clinical decision support system (CDSS). The Allergic Rhinitis & its Impact on Asthma (ARIA) guideline position MP-AzeFlu firstline for the treatment of AR, and in preference to intranasal corticosteroids (INSs) during the first 2 weeks of treatment. The AR CDSS recommends MP-AzeFlu as one of the firstline treatments for patients with a visual analogue scale (VAS) score lower than 5/10 cm, and in preference (along with INS) for those with a VAS score equal or higher than5/10 cm. Panellists agreed that AR management should be kept as simple as possible, with some preferring a one treatment fits all approach, while others preferred a step-up approach. The need to change the AR management mentality was acknowledged, accepting that most patients use their medication as needed and use multiple treatments; AR medications are needed which have a very fast onset of action and which target breakthrough symptoms. Panellists agreed that MP-AzeFlu has a role to play here, since it has a 5 minute onset-of-action, provides clinically-relevant symptom relief in 15 mins and AR control in less than 3 days, targets nasal hyper-reactivity (NHR) which likely contributes to uncontrolled AR and breakthrough symptoms, and provides more effective AR symptom relief than INS monotherapy or INS + oral antihistamine. Finally, experts considered it likely that MP-AzeFlu should have a greater impact on asthma control than INS in co-morbid patients, but clinical data is required to back up existing pharmacoeconomic evidence. The next Rhinology Future Debate will be in held in Brussels in Dec 2019.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Scadding G, Bousquet J, Bachert C, et al. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. Rhinology. 2019. PMID: 30052697. doi:10.4193/Rhin18.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。